Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 52.6% in the second quarter, Holdings Channel.com reports. The fund owned 1,982 shares of the biopharmaceutical company’s stock after selling 2,202 shares during the period. QRG Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,041,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of REGN. Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares in the last quarter. NBC Securities Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $78,000. Capital Investment Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 44.1% during the 1st quarter. Capital Investment Advisors LLC now owns 438 shares of the biopharmaceutical company’s stock worth $278,000 after purchasing an additional 134 shares in the last quarter. Daymark Wealth Partners LLC increased its stake in shares of Regeneron Pharmaceuticals by 52.5% during the 1st quarter. Daymark Wealth Partners LLC now owns 523 shares of the biopharmaceutical company’s stock worth $332,000 after purchasing an additional 180 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 9.6% during the 1st quarter. Farther Finance Advisors LLC now owns 628 shares of the biopharmaceutical company’s stock worth $387,000 after purchasing an additional 55 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 3.3%

Shares of NASDAQ REGN opened at $563.86 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,024.36. The firm has a fifty day moving average of $573.34 and a 200-day moving average of $566.14. The stock has a market capitalization of $59.76 billion, a PE ratio of 14.21, a P/E/G ratio of 1.86 and a beta of 0.31. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. During the same period in the previous year, the company earned $11.56 EPS. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on REGN shares. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research note on Monday, August 4th. UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Citigroup reaffirmed a “buy” rating and issued a $650.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Finally, Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price for the company. in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.